Work

Identification and characterization of HIV-1 specific neutralizing antibodies from HIV-1 seropositive patients and autoimmune (HIV-1 seropositive or seronegative) participants.

Year: 2011
Type: dissertation
Study design: Observational Study
Abstract: Since the discovery of HIV-1, the production of an effective prophylactic or \ntherapeutic vaccine remains elusive. An effective vaccine must be able to elicit a \npotent humoral and cellular immune response. Neutralizing antibodies target the \nenvelope glycoproteins on the surface of HIV-1 virions thereby preventing viral \nentry. Unfortunately, to date only a handful of neutralizing antibodies have been \nidentified that are capable of neutralizing different viral strains within diverse \nsubtypes, and none have been isolated from HIV-1 subtype C infected patients. In \nthis study, we screened four different HIV-1 subtype C infected patient cohorts for \nthe presence of neutralizing antibodies against a panel of 5 subtype C and 1 \nsubtype B pseudovirus/es in a pseudovirion based neutralizing antibody assay. \nThe CT cohort comprised 9 slow progressor plasma samples, the FV cohort \nconsisted of 11 antiretroviral drug naïve HIV-1 subtype C infected plasma \nsamples. Plasma samples from 10 antiretroviral treatment experienced HIV-1 \nsubtype C infected patients failing first line therapy made up the DR cohort and the \nJM cohort consisted of 10 serum samples from HIV-1 seropositive or seronegative \nindividuals with an autoimmune disorder. A pseudovirion neutralizing antibody \nassay was successfully established, and all plasma and serum samples were heat \ninactivated and screened using this assay. Analysis of the percentage \nneutralization and IC50 data showed no correlation between the presence of \nneutralizing antibodies and delayed disease progression in the SP cohort. High \nlevels of neutralizing antibodies were observed in the DR cohort, however future \nstudies are required to confirm if the measured neutralization is due to residual \nantiretroviral drugs in the plasma or neutralizing antibodies. No samples within the FV cohort showed promising neutralizing antibody activity however the JM cohort \nharboured 3 serum samples (TN5, TN6 and TN8) that exhibited a greater than \naverage breadth of neutralization and are worth investigating further in future \nstudies. Patients TN5, TN6 and TN8 were all HIV-1 positive with an additional \nautoimmune disease. The availability of stored bone marrow samples for TN5, \nTN6 and TN8 will allow for the generation of antibody phage display libraries and \nisolation of monoclonal antibodies, with potentially broadly cross reactive activity.
Language: English
Subfield: Virology
Open Access status: green
OpenAlex ID: W2125940032
Cites: 201
Cited by:
Related to: 10